John Overdeck’s Metacrine, Inc. Common Stock MTCR Stock Holding History

John Overdeck’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,035	Closed	-$14K	–	3110
2022 Q1	$14K	Buy	+23,035	New	+$12.1K	﹤0.01%	2535
2021 Q4	–	Sell	-123,659	Closed	-$424K	–	5089
2021 Q3	$424K	Buy	123,659 +58,836	+91%	+$183K	﹤0.01%	3392
2021 Q2	$246K	Buy	+64,823	New	+$268K	﹤0.01%	3642

Other funds holding MTCR

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

John Overdeck's MTCR Position: Q2 2022 in Review

John Overdeck sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2022, closing a stake of 23,035 shares — an estimated $14K sold.

John Overdeck first reported a position in MTCR in Q2 2021 and held it in 3 quarters. The position peaked at $424K in Q3 2021. 25 funds tracked by Wall St. Rank hold MTCR as of Q2 2022.

John Overdeck reported no remaining Metacrine, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
John Overdeck sold 23,035 Metacrine, Inc. Common Stock shares in Q2 2022, an estimated $14K.
John Overdeck first reported a position in Metacrine, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
John Overdeck's Metacrine, Inc. Common Stock position peaked at $424K in Q3 2021.
25 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.